Recombinant OC126 (Abagovomab Biosimilar) antibody
The Human Monoclonal anti-OC126 (Abagovomab Biosimilar) antibody is suitable to detect OC126 (Abagovomab Biosimilar) in samples from Mouse. It has been validated for ELISA and WB.
Catalog No. ABIN7538052
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant OC126 (Abagovomab Biosimilar) antibody (ABIN7538052)
Target
OC126 (Abagovomab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Mouse
Host
Human
Clonality
Monoclonal
Conjugate
This OC126 (Abagovomab Biosimilar) antibody is un-conjugated
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Abagovomab Biosimilar - Anti-idiotope of anti-Mus musculus monoclonal antibody OC126 mAb - Research Grade
-
Characteristics
- Antibody Type: idiotypic IgG1-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
Isotype
- IgG1 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- OC126 (Abagovomab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). Abagovomab has been developed by the pharmaceutical company Menarini for the treatment of ovarian cancer. It (ab2) shows high affinity for the paratope of ab1, and binding of ab2 to Ab1 is almost completely inhibited (93%) by the nominal antigen. The administration of F(ab')2 fragments of abagovomab to rats produces anti-CA-125 immunity with the production of IgG and IgM anti-anti-idiotypic antibodies (ab3) that bind both to abagovomab and CA-125. Non-MHC restricted cell-mediated cytotoxicity for NIH OVCAR3 cell lines is also demonstrated.
-
CAS-No
- 792921-10-9
Target
-
You are here:
